Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
An expert oncologist stated that if the drug is approved, he would not use it broadly. He would reserve it for a highly selective niche of high-risk patients who fail initial therapies and have specific NGS biomarkers. This signals a potential disconnect between a formal approval and real-world clinical utility.
Related Insights
A potential unstated argument for approving capivasertib, despite its borderline data, was the fear that a rejection would kill the entire field of AKT inhibitors. This suggests that broader strategic concerns about fostering innovation can sometimes influence regulatory recommendations more than a single drug's specific risk-benefit profile.
The CAPITELLO-281 trial showed the AKT inhibitor capivasertib delayed disease progression in PTEN-deficient prostate cancer. However, without a demonstrated overall survival benefit yet, its path to becoming a new standard of care is uncertain. This highlights the growing debate over whether delaying progression is a sufficient endpoint to justify added toxicities when survival isn't improved.
The LEAP-010 trial excluded patients with vascular involvement due to the drug's bleeding risk. This is a common characteristic in real-world head and neck cancer patients, especially post-radiation. This discrepancy means that even if the drug combination had been successful, its applicability in routine clinical practice would be severely limited.
The drug is already approved in breast cancer with a stronger PFS benefit (HR 0.5-0.6) and lower toxicity. Its weaker data in prostate cancer (HR 0.81, 60% grade 3 toxicity) demonstrates that the same drug faces a much higher regulatory bar when the benefit-risk calculation is less favorable in a new disease context.
When a highly effective therapy like EV Pembro was approved for 'cisplatin ineligible' patients, the definition of 'ineligible' became very elastic in practice. This demonstrates that when a new treatment is seen as transformative, clinicians find ways to qualify patients, putting pressure on established guidelines.
Despite acknowledging that a one-size-fits-all treatment duration is suboptimal, the expert consensus is to follow the study protocol. This conservative, evidence-based approach prevails due to the absence of validated biomarkers, like ctDNA, to safely guide treatment de-escalation for individual patients.
The FDA is predicted to approve new PARP inhibitors from trials like AMPLITUDE only for BRCA-mutated patients, restricting use to where data is strongest. This contrasts with the EMA's potential for broader approvals or denials. This highlights the diverging regulatory philosophies that create different drug access landscapes in the US and Europe.
Despite some positive clinical trial data for AKT inhibitors in prostate cancer, expert opinion suggests this class of drugs is unlikely to see the light of day in routine clinical practice. Skepticism remains about their overall impact, with a feeling that they do not represent a new, meaningful chapter for treatment.
Applying traditional, broad primary care launch strategies to highly targeted specialty therapies is a major risk. The complexity of stakeholders and decision-making in areas like oncology means old playbooks can make a company's efforts completely irrelevant.
Even when a new drug like zanidatumab is proven superior, experienced clinicians are reluctant to use it on their most frail or borderline-performance patients immediately. They prefer to gain real-world experience managing its side effects in more robust individuals before expanding use to these more complex cases.
